1. Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom;
2. Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary;
3. MLL Munich Leukemia Laboratory GmbH, Munich, Germany;
4. Center for Thrombosis and Hemostasis, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany;
5. Department of Pathology, British Columbia Cancer Centre, Vancouver, BC, Canada;
6. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;
7. Institute of Pathology, University of Würzburg, Würzburg, Germany;
8. Department of Clinical Pathology, and Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany;
9. Department of Pathology, Hospital Clinic, University of Barcelona, Barcelona, Spain;
10. Department of Pathology, University of Arizona Cancer Centre, Tucson, AZ;
11. Department of Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;
12. Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway;
13. Department of Pathology, University of Nebraska Medical Centre, Omaha, NE;
14. Department of Pathology, Oregon Health and Science University, Portland, OR;
15. Metabolism Branch, National Cancer Institute, Bethesda, MD;
16. HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, and Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY; and
17. Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom